Show simple item record

dc.contributor.authorBogdanov, Alexei A. Jr.
dc.contributor.authorMazzanti, Mary L.
dc.date2022-08-11T08:10:50.000
dc.date.accessioned2022-08-23T17:21:49Z
dc.date.available2022-08-23T17:21:49Z
dc.date.issued2011-02-01
dc.date.submitted2015-01-05
dc.identifier.citationSemin Oncol. 2011 Feb;38(1):42-54. doi: 10.1053/j.seminoncol.2010.11.002. <a href="http://dx.doi.org/10.1053/j.seminoncol.2010.11.002">Link to article on publisher's site</a>
dc.identifier.issn0093-7754 (Linking)
dc.identifier.doi10.1053/j.seminoncol.2010.11.002
dc.identifier.pmid21362515
dc.identifier.urihttp://hdl.handle.net/20.500.14038/48612
dc.description.abstractMagnetic resonance imaging (MRI) is a powerful diagnostic tool with unsurpassed spatial resolution that is capable of providing detailed information about the structure and composition of tumors. The use of exogenously administered contrast agents allows compartment-specific enhancement of tumors, enabling imaging of functional blood and interstitial volumes. Current efforts are directed at enhancing the capabilities of MRI in oncology by adding contrast agents with molecular specificities to the growing armamentarium of diagnostic probes that produce signal by changing local proton relaxation times as a consequence of specific contrast agent binding to cell surface receptors or extracellular matrix components. We review herein the most notable examples, illustrating major trends in the development of specific probes for high-resolution imaging in molecular oncology.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=21362515&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3080112/
dc.subjectContrast Media
dc.subjectHumans
dc.subjectMagnetic Resonance Imaging
dc.subjectMolecular Imaging
dc.subjectMolecular Probes
dc.subjectNeoplasms
dc.subjectDiagnosis
dc.subjectEquipment and Supplies
dc.subjectInvestigative Techniques
dc.subjectNeoplasms
dc.subjectRadiology
dc.titleMolecular magnetic resonance contrast agents for the detection of cancer: past and present
dc.typeJournal Article
dc.source.journaltitleSeminars in oncology
dc.source.volume38
dc.source.issue1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/radiology_pubs/99
dc.identifier.contextkey6497753
html.description.abstract<p>Magnetic resonance imaging (MRI) is a powerful diagnostic tool with unsurpassed spatial resolution that is capable of providing detailed information about the structure and composition of tumors. The use of exogenously administered contrast agents allows compartment-specific enhancement of tumors, enabling imaging of functional blood and interstitial volumes. Current efforts are directed at enhancing the capabilities of MRI in oncology by adding contrast agents with molecular specificities to the growing armamentarium of diagnostic probes that produce signal by changing local proton relaxation times as a consequence of specific contrast agent binding to cell surface receptors or extracellular matrix components. We review herein the most notable examples, illustrating major trends in the development of specific probes for high-resolution imaging in molecular oncology.</p>
dc.identifier.submissionpathradiology_pubs/99
dc.contributor.departmentDepartment of Radiology
dc.source.pages42-54


This item appears in the following Collection(s)

Show simple item record